Charles Xing

发表

Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.

C. Sage, B. Fioravanti, Albert S. Ren, 2011, Bioorganic & medicinal chemistry letters.

Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration

I. Gaidarov, John M Frazer, D. Unett, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC

J. Short, W. J. Boyle, G. Frey, 2018, Experimental and Molecular Therapeutics.

Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.

D. Sengupta, Michael E. Morgan, K. Whelan, 2012, Bioorganic & medicinal chemistry letters.

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.

William Thomsen, B. Fioravanti, Albert S. Ren, 2008, Journal of medicinal chemistry.

N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.

Robert M. Jones, D. Unett, D. Behan, 2010, Molecular endocrinology.

Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

L. Steinman, J. Short, W. J. Boyle, 2021, Proceedings of the National Academy of Sciences.

Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists.

C. Sage, Robert M. Jones, Yinghong Gao, 2011, Bioorganic & medicinal chemistry letters.

Abstract 833: Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC

J. Short, W. J. Boyle, G. Frey, 2018, Experimental and Molecular Therapeutics.

Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.

D. Sengupta, Michael E. Morgan, K. Whelan, 2012, Bioorganic & medicinal chemistry letters.

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

G. Frey, Haizhen Liu, C. Wheeler, 2024, mAbs.